Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets, for oral use IMBRUVICA ® (ibrutinib) oral suspension Initial U.S. Approval: 2013
Medication labelWhy this: Advisory · dailymed-prescription
IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
- generic_name
- ibrutinib
- product_names
- Ibrutinib
- ndc
- 57962-070, 57962-070-28, 57962-140, 57962-140-09, 57962-140-12, 57962-014, 57962-014-28, 57962-280, 57962-280-28, 57962-420, 57962-420-28, 57962-420-71, 57962-007, 57962-007-12
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en